TAG:
cap
Competitive Bidding: A Growing Threat to Labs
CEO SUMMARY: When it comes to competitive bidding for laboratory testing services, Medicare is no longer the only government health program looking to save money through this method. Florida’s Medicaid program and the British Columbia health system are both moving forward with plans to …
Arguing in Favor of Regional Laboratory Networks
TWO STORIES IN THIS ISSUE OF THE DARK REPORT DEMONSTRATE why regional laboratory networks are a business model which should be revisited by hospital laboratories with outreach programs. Seattle provides a great example of how an existing laboratory network gives hospitals in that region an addition…
Florida Issues State RFP For Sole Medicaid Lab
CEO SUMMARY: If competitive bidding for Medicare business is something universally viewed as bad by the laboratory industry, then the lab services RFP issued by Florida’s Medicaid program must be considered a serious threat to the status quo. Further, the fact that Medicaid officials in…
LabCorp Buys MDS Labs In New York and Georgia
CEO SUMMARY: It’s the final chapter of the “Canadian Invasion” of the U.S. laboratory testing market. In the mid-1990s, both MDS and Dynacare built a sizeable presence in the United States as they both worked to develop joint ventures with hospital laboratories. Dynacare was acquire…
Seattle Hospital Lab JVs Involve Quest & LabCorp
CEO SUMMARY: Joint ventures and collaborative business relationships between hospital laboratories and commercial laboratories continue to be a difficult business model. Recent events in Seattle demonstrate the challenges and frustrations of establishing such ventures, then making them su…
Welsh Carson Pays $1.14 Billion To Acquire U.S. Oncology, Inc.
EVEN AS THE LAST ISSUE of THE DARK REPORT was reaching clients with news of Genzyme Corp.’s offer to buy IMPATH Inc., another big oncology deal was announced. On March 22, 2004, Welsh, Carson, Anderson & Stowe announced an offer of $15.05 per …
AmeriPath Reports on 2003, Its First Year as a Private Firm
WILL BUSINESS BE BETTER for AmeriPath, Inc. as a private company than it was as a publicly-traded firm? Its 2003 financial report indicates some interesting challenges, many common to all laboratories. First, a look at basic numbers. AmeriPath’s net revenues grew from $478.8 milli…
“April 5, 2004 Intelligence: Late Breaking Lab News”
There’s a new national lab company ready to compete. This week American Esoterix Laboratories, Inc. (AEL) announced it was open and ready for business. Based in Brentwood, Tennessee, it has already completed two lab acquisitions (ThromboCare Laboratories and …
Oncology Diagnostics Attracts Big Money
MORE SURPRISING DEVELOPMENTS for the anatomic pathology profession during the past three weeks! The impending $215 million acquisition of IMPATH, Inc. by Genzyme Corporation, announced on March 1, has the …
IMPATH Has a Buyer: Genzyme Pays $215 Mil
CEO SUMMARY: Two unexpected things happened in IMPATH’s Chapter 11 bankruptcy action. First, it attracted a buyer willing to pay the premium price of $215 million for its assets. Second, the buyer was not another laboratory company. Rather, it is a new entrant into the oncology diagnost…
CURRENT ISSUE
Volume XXXIII, No. 4 – March 23, 2026
A federal court ruling has established a safe harbor for clinical labs when they run tests ordered by physicians. Lab leaders should examine this briefing for pitfalls. Also, it turns out that providers may be ordering inappropriate vitamin D tests, according to one expert.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.